Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 52Triple Negative Breast Neoplasms 10Lung Neoplasms 6Stomach Neoplasms 5Advanced Breast Cancer 4Sarcoma 3Neoplasm Metastasis 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic HER2-positive Breast Cancer With Brain Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Breast Cancer × Injections × Breast × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡